SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'EQG'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EQB_A_FFOA1293_1 (SERINE HYDROXYMETHYLTRANSFE RASE)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	3 / 3	GLU A 141 TYR A 139 PHE A 180	EQG A 504 (-2.0A) EQG A 504 (-3.2A) EQG A 504 (-3.1A)	0.96A	1eqbB-6c4gA: undetectable	1eqbB-6c4gA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EQB_B_FFOB2293_0 (SERINE HYDROXYMETHYLTRANSFE RASE)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	3 / 3	GLU A 141 TYR A 139 PHE A 180	EQG A 504 (-2.0A) EQG A 504 (-3.2A) EQG A 504 (-3.1A)	0.96A	1eqbA-6c4gA: undetectable	1eqbA-6c4gA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EQB_C_FFOC3293_2 (SERINE HYDROXYMETHYLTRANSFE RASE)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	3 / 3	GLU A 141 TYR A 139 PHE A 180	EQG A 504 (-2.0A) EQG A 504 (-3.2A) EQG A 504 (-3.1A)	0.96A	1eqbD-6c4gA: undetectable	1eqbD-6c4gA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EQB_D_FFOD4293_0 (SERINE HYDROXYMETHYLTRANSFE RASE)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	3 / 3	GLU A 141 TYR A 139 PHE A 180	EQG A 504 (-2.0A) EQG A 504 (-3.2A) EQG A 504 (-3.1A)	0.97A	1eqbC-6c4gA: undetectable	1eqbC-6c4gA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2V0Z_C_C41C1328_1 (RENIN)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	7 / 12	ASP A 80 GLY A 82 SER A 83 TYR A 139 VAL A 188 ASP A 313 GLY A 315	EQG A 504 (-2.5A) EQG A 504 (-3.0A) EQG A 504 (-4.3A) EQG A 504 (-3.2A) None EQG A 504 (-2.1A) EQG A 504 (-3.5A)	0.45A	2v0zC-6c4gA: 33.8	2v0zC-6c4gA: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2V0Z_C_C41C1328_1 (RENIN)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 12	ASP A 313 GLY A 315 ASP A 80 GLY A 82 SER A 84	EQG A 504 (-2.1A) EQG A 504 (-3.5A) EQG A 504 (-2.5A) EQG A 504 (-3.0A) EDO A 506 (-3.1A)	0.86A	2v0zC-6c4gA: 33.8	2v0zC-6c4gA: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2V0Z_C_C41C1328_1 (RENIN)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	6 / 12	ASP A 313 GLY A 315 SER A 316 ASP A 80 GLY A 82 SER A 192	EQG A 504 (-2.1A) EQG A 504 (-3.5A) EQG A 504 (-3.3A) EQG A 504 (-2.5A) EQG A 504 (-3.0A) EDO A 506 (-3.0A)	1.31A	2v0zC-6c4gA: 33.8	2v0zC-6c4gA: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2V0Z_O_C41O1327_1 (RENIN)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 12	ASP A 80 GLY A 82 VAL A 188 ASP A 313 GLY A 315	EQG A 504 (-2.5A) EQG A 504 (-3.0A) None EQG A 504 (-2.1A) EQG A 504 (-3.5A)	0.33A	2v0zO-6c4gA: 34.1	2v0zO-6c4gA: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2V0Z_O_C41O1327_1 (RENIN)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 12	ASP A 313 GLY A 315 ASP A 80 GLY A 82 SER A 84	EQG A 504 (-2.1A) EQG A 504 (-3.5A) EQG A 504 (-2.5A) EQG A 504 (-3.0A) EDO A 506 (-3.1A)	0.82A	2v0zO-6c4gA: 34.1	2v0zO-6c4gA: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3BUF_A_AEGA394_0 (BETA-SECRETASE 1)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	4 / 5	LEU A 311 ASP A 313 ILE A 439 GLY A 82	EQG A 504 ( 4.2A) EQG A 504 (-2.1A) EQG A 504 (-4.3A) EQG A 504 (-3.0A)	0.53A	3bufA-6c4gA: 32.6	3bufA-6c4gA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3D91_B_REMB350_1 (RENIN)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 12	ASP A 80 GLY A 82 VAL A 188 LEU A 311 ASP A 313	EQG A 504 (-2.5A) EQG A 504 (-3.0A) None EQG A 504 ( 4.2A) EQG A 504 (-2.1A)	0.57A	3d91B-6c4gA: 33.8	3d91B-6c4gA: 14.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3PWW_A_ROCA1001_2 (ENDOTHIAPEPSIN)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 8	GLY A 82 SER A 83 TYR A 139 ASP A 313 THR A 317	EQG A 504 (-3.0A) EQG A 504 (-4.3A) EQG A 504 (-3.2A) EQG A 504 (-2.1A) EQG A 504 (-2.9A)	0.19A	3pwwA-6c4gA: 32.0	3pwwA-6c4gA: 13.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3PWW_A_ROCA1001_2 (ENDOTHIAPEPSIN)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 8	GLY A 82 TYR A 139 SER A 143 ASP A 313 THR A 317	EQG A 504 (-3.0A) EQG A 504 (-3.2A) EQG A 504 ( 4.3A) EQG A 504 (-2.1A) EQG A 504 (-2.9A)	0.49A	3pwwA-6c4gA: 32.0	3pwwA-6c4gA: 13.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3Q70_A_RITA2001_1 (CANDIDAPEPSIN-2)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	6 / 12	ILE A 78 ASP A 80 GLY A 82 SER A 143 ASP A 313 ILE A 439	EQG A 504 ( 3.8A) EQG A 504 (-2.5A) EQG A 504 (-3.0A) EQG A 504 ( 4.3A) EQG A 504 (-2.1A) EQG A 504 (-4.3A)	0.45A	3q70A-6c4gA: 8.7	3q70A-6c4gA: 16.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TNE_A_RITA401_1 (SECRETED ASPARTIC PROTEASE)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	6 / 12	ILE A 78 ASP A 80 GLY A 82 SER A 143 ASP A 313 ILE A 439	EQG A 504 ( 3.8A) EQG A 504 (-2.5A) EQG A 504 (-3.0A) EQG A 504 ( 4.3A) EQG A 504 (-2.1A) EQG A 504 (-4.3A)	0.65A	3tneA-6c4gA: 30.7	3tneA-6c4gA: 12.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3TNE_B_RITB401_1 (SECRETED ASPARTIC PROTEASE)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	6 / 12	ILE A 78 ASP A 80 GLY A 82 SER A 143 ASP A 313 ILE A 439	EQG A 504 ( 3.8A) EQG A 504 (-2.5A) EQG A 504 (-3.0A) EQG A 504 ( 4.3A) EQG A 504 (-2.1A) EQG A 504 (-4.3A)	0.68A	3tneB-6c4gA: 30.6	3tneB-6c4gA: 12.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ESK_A_1YNA701_1 (LANOSTEROL 14-ALPHA DEMETHYLASE)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 12	GLY A 315 TYR A 135 TYR A 149 GLY A 198 THR A 81	EQG A 504 (-3.5A) None None None None	1.14A	5eskA-6c4gA: undetectable	5eskA-6c4gA: 11.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ESL_A_1YNA701_1 (LANOSTEROL 14-ALPHA DEMETHYLASE)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 12	GLY A 315 TYR A 135 TYR A 149 GLY A 198 THR A 81	EQG A 504 (-3.5A) None None None None	1.16A	5eslA-6c4gA: undetectable	5eslA-6c4gA: 11.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6A93_B_8NUB3001_0 (5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562)	6c4g	ASPARTIC PROTEASE PM5 (Plasmodium vivax)	5 / 12	TYR A 286 VAL A 291 SER A 406 LEU A 311 VAL A 281	EDO A 506 (-4.2A) None None EQG A 504 ( 4.2A) None	1.34A	6a93B-6c4gA: undetectable	6a93B-6c4gA: undetectable

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1EQB_A_FFOA1293_1","SERINE HYDROXYMETHYLTRANSFERASE","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",3,"GLU A 141;TYR A 139;PHE A 180","EQG A 504 (-2.0A);EQG A 504 (-3.2A);EQG A 504 (-3.1A)","0.96A","1eqbB-6c4gA:undetectable",null],["1EQB_B_FFOB2293_0","SERINE HYDROXYMETHYLTRANSFERASE","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",3,"GLU A 141;TYR A 139;PHE A 180","EQG A 504 (-2.0A);EQG A 504 (-3.2A);EQG A 504 (-3.1A)","0.96A","1eqbA-6c4gA:undetectable","1eqbB-6c4gA:undetectable"],["1EQB_C_FFOC3293_2","SERINE HYDROXYMETHYLTRANSFERASE","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",3,"GLU A 141;TYR A 139;PHE A 180","EQG A 504 (-2.0A);EQG A 504 (-3.2A);EQG A 504 (-3.1A)","0.96A","1eqbD-6c4gA:undetectable","1eqbA-6c4gA:undetectable"],["1EQB_D_FFOD4293_0","SERINE HYDROXYMETHYLTRANSFERASE","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",3,"GLU A 141;TYR A 139;PHE A 180","EQG A 504 (-2.0A);EQG A 504 (-3.2A);EQG A 504 (-3.1A)","0.97A","1eqbC-6c4gA:undetectable","1eqbD-6c4gA:undetectable"],["2V0Z_C_C41C1328_1","RENIN","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",7,"ASP A  80;GLY A  82;SER A  83;TYR A 139;VAL A 188;ASP A 313;GLY A 315","EQG A 504 (-2.5A);EQG A 504 (-3.0A);EQG A 504 (-4.3A);EQG A 504 (-3.2A);None;EQG A 504 (-2.1A);EQG A 504 (-3.5A)","0.45A","2v0zC-6c4gA:33.8","1eqbC-6c4gA:undetectable"],["2V0Z_C_C41C1328_1","RENIN","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"ASP A 313;GLY A 315;ASP A  80;GLY A  82;SER A  84","EQG A 504 (-2.1A);EQG A 504 (-3.5A);EQG A 504 (-2.5A);EQG A 504 (-3.0A);EDO A 506 (-3.1A)","0.86A","2v0zC-6c4gA:33.8","2v0zC-6c4gA:14.11"],["2V0Z_C_C41C1328_1","RENIN","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",6,"ASP A 313;GLY A 315;SER A 316;ASP A  80;GLY A  82;SER A 192","EQG A 504 (-2.1A);EQG A 504 (-3.5A);EQG A 504 (-3.3A);EQG A 504 (-2.5A);EQG A 504 (-3.0A);EDO A 506 (-3.0A)","1.31A","2v0zC-6c4gA:33.8","2v0zC-6c4gA:14.11"],["2V0Z_O_C41O1327_1","RENIN","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"ASP A  80;GLY A  82;VAL A 188;ASP A 313;GLY A 315","EQG A 504 (-2.5A);EQG A 504 (-3.0A);None;EQG A 504 (-2.1A);EQG A 504 (-3.5A)","0.33A","2v0zO-6c4gA:34.1","2v0zC-6c4gA:14.11"],["2V0Z_O_C41O1327_1","RENIN","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"ASP A 313;GLY A 315;ASP A  80;GLY A  82;SER A  84","EQG A 504 (-2.1A);EQG A 504 (-3.5A);EQG A 504 (-2.5A);EQG A 504 (-3.0A);EDO A 506 (-3.1A)","0.82A","2v0zO-6c4gA:34.1","2v0zO-6c4gA:14.11"],["3BUF_A_AEGA394_0","BETA-SECRETASE 1","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",4,"LEU A 311;ASP A 313;ILE A 439;GLY A  82","EQG A 504 ( 4.2A);EQG A 504 (-2.1A);EQG A 504 (-4.3A);EQG A 504 (-3.0A)","0.53A","3bufA-6c4gA:32.6","2v0zO-6c4gA:14.11"],["3D91_B_REMB350_1","RENIN","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"ASP A  80;GLY A  82;VAL A 188;LEU A 311;ASP A 313","EQG A 504 (-2.5A);EQG A 504 (-3.0A);None;EQG A 504 ( 4.2A);EQG A 504 (-2.1A)","0.57A","3d91B-6c4gA:33.8","3bufA-6c4gA:undetectable"],["3PWW_A_ROCA1001_2","ENDOTHIAPEPSIN","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"GLY A  82;SER A  83;TYR A 139;ASP A 313;THR A 317","EQG A 504 (-3.0A);EQG A 504 (-4.3A);EQG A 504 (-3.2A);EQG A 504 (-2.1A);EQG A 504 (-2.9A)","0.19A","3pwwA-6c4gA:32.0","3d91B-6c4gA:14.11"],["3PWW_A_ROCA1001_2","ENDOTHIAPEPSIN","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"GLY A  82;TYR A 139;SER A 143;ASP A 313;THR A 317","EQG A 504 (-3.0A);EQG A 504 (-3.2A);EQG A 504 ( 4.3A);EQG A 504 (-2.1A);EQG A 504 (-2.9A)","0.49A","3pwwA-6c4gA:32.0","3pwwA-6c4gA:13.98"],["3Q70_A_RITA2001_1","CANDIDAPEPSIN-2","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",6,"ILE A  78;ASP A  80;GLY A  82;SER A 143;ASP A 313;ILE A 439","EQG A 504 ( 3.8A);EQG A 504 (-2.5A);EQG A 504 (-3.0A);EQG A 504 ( 4.3A);EQG A 504 (-2.1A);EQG A 504 (-4.3A)","0.45A","3q70A-6c4gA:8.7","3pwwA-6c4gA:13.98"],["3TNE_A_RITA401_1","SECRETED ASPARTIC PROTEASE","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",6,"ILE A  78;ASP A  80;GLY A  82;SER A 143;ASP A 313;ILE A 439","EQG A 504 ( 3.8A);EQG A 504 (-2.5A);EQG A 504 (-3.0A);EQG A 504 ( 4.3A);EQG A 504 (-2.1A);EQG A 504 (-4.3A)","0.65A","3tneA-6c4gA:30.7","3q70A-6c4gA:16.54"],["3TNE_B_RITB401_1","SECRETED ASPARTIC PROTEASE","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",6,"ILE A  78;ASP A  80;GLY A  82;SER A 143;ASP A 313;ILE A 439","EQG A 504 ( 3.8A);EQG A 504 (-2.5A);EQG A 504 (-3.0A);EQG A 504 ( 4.3A);EQG A 504 (-2.1A);EQG A 504 (-4.3A)","0.68A","3tneB-6c4gA:30.6","3tneA-6c4gA:12.76"],["5ESK_A_1YNA701_1","LANOSTEROL 14-ALPHA DEMETHYLASE","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"GLY A 315;TYR A 135;TYR A 149;GLY A 198;THR A  81","EQG A 504 (-3.5A);None;None;None;None","1.14A","5eskA-6c4gA:undetectable","3tneB-6c4gA:12.76"],["5ESL_A_1YNA701_1","LANOSTEROL 14-ALPHA DEMETHYLASE","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"GLY A 315;TYR A 135;TYR A 149;GLY A 198;THR A  81","EQG A 504 (-3.5A);None;None;None;None","1.16A","5eslA-6c4gA:undetectable","5eskA-6c4gA:11.02"],["6A93_B_8NUB3001_0","5-HYDROXYTRYPTAMINE RECEPTOR 2A,SOLUBLE CYTOCHROME B562","6c4g","ASPARTIC PROTEASE PM5","Plasmodium vivax",5,"TYR A 286;VAL A 291;SER A 406;LEU A 311;VAL A 281","EDO A 506 (-4.2A);None;None;EQG A 504 ( 4.2A);None","1.34A","6a93B-6c4gA:undetectable","5eslA-6c4gA:11.02"]]